SPINK2 and acute myeloid leukemia: Survival analyses were initially performed on the whole cohort (N = 137), which comprised only de novo AML patients treated with the DA 3 + 7 protocol, and subsequently on specific subgroups that had significant associations with SPINK2 expression: IR risk (by cytogenetics and the ELN2022 criteria), CN-AML and NPM1mut-AML.